Polyadenylic.polyuridylic acid in the cotreatment of cancer.
The biological properties of polyadenylic . polyuridylic acid (Poly(A) . Poly(U] are discussed and the application to the treatment of cancer in various animal models is described. Pharmacokinetic properties are presented and the results of clinical application to humans with specific reference to adjuvant treatment of breast cancer are examined in some detail. Given these results and the total lack of toxicity or of secondary effects of Poly(A) . Poly(U) it appears that further development and application of this polynucleotide complex are certainly justified in terms of clinical use in cancer and perhaps in viral pathologies.
Michelson
A M
AM
Lacour
F
F
Lacour
J
J
D015088:2',5'-Oligoadenylate Synthetase / Q000097:blood; D000818:Animals; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D007700:Kinetics; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009369:Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000628:therapy; D011063:Poly A-U / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D011494:Protein Kinases / Q000097:blood; D014018:Tissue Distribution
D011063:Poly A-U; D007372:Interferons; D011494:Protein Kinases; D015088:2',5'-Oligoadenylate Synthetase